Updated SITC data bring NextCure back to earth

While a lack of additional reponses in the latest data from NextCure for NC318 disappointed investors Monday, the results for the SIGLEC15 mAb are still comparable to early monotherapy data for PD-1/PD-L1 inhibitors.

None of the six new patients in the non-small cell lung cancer (NSCLC) cohort of the Phase I trial had a partial or complete response, bringing down the observed response rate (ORR) to 15% from 27% reported in an abstract released ahead of the Society for Immunotherapy of Cancer (SITC) meeting. ...